<DOC>
	<DOCNO>NCT00892125</DOCNO>
	<brief_summary>The purpose study evaluate effect potent metabolic enzyme inducer , carbamazepine , steady-state pharmacokinetics orally administer paliperidone ER evaluate safety tolerability treatment clinically stable patient diagnosis schizophrenia bipolar I disorder .</brief_summary>
	<brief_title>A Study Effect Carbamazepine Pharmacokinetics Paliperidone Extended Release ( ER ) Patients With Schizophrenia Bipolar I Disorder</brief_title>
	<detailed_description>The current study design open-label , multiple-center , multiple-dose , 2 treatment , 2 period sequential drug interaction study . It consist 3 phase : screen phase begin within 21 day first study drug administration ; open label treatment phase consist 2 treatment period ( Period 1 Period 2 ) , patient receive multiple oral dos 6-mg paliperidone ER alone combination multiple oral dos carbamazepine , end study evaluation upon completion study procedure Period 2 early withdrawal . There washout period treatment period . Given potential concomitant use carbamazepine antipsychotic , paliperidone ER , treatment schizophrenia bipolar I disorder , study design investigate effect carbamazepine steady-state pharmacokinetics paliperidone ER . Safety tolerability monitor throughout study.. Period 1 : 6 mg paliperidone ER daily Day 1 Day 7 , route oral ; Period 2 : 6 mg paliperidone ER daily carbamazepine 200 mg twice daily Day 8 Day 28 , route oral .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>Diagnosis schizophrenia subtype ( 295.10 295.20 295.30 295.60 295.90 ) bipolar I disorder ( 296.0x , 296.4x , 296.5x , 296.6x 296.7 ) , accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) Clinically stable psychiatric hospitalization change exist mood stabilizer , antipsychotic , antimanic drug 3 month screen . A reduction dose exist medication acceptable subject remain clinically stable throughout 3 month period . In addition , increase decrease dose mood stabilizer basis therapeutic drug monitoring substitution specific mood stabilizer , antipsychotic , antimanic drug another poor tolerability allow within 3 month screen Have CGIS score 3 less baseline screen Body mass index ( BMI , weight [ kg ] /height [ m2 ] ) 18 35 kg/m2 , inclusive Have supine ( 5 minute rest ) blood pressure 100 140 mmHg systolic , inclusive , 50 90 mmHg diastolic , inclusive Apart abovementioned diagnosis , otherwise healthy basis prestudy physical examination , medical history , 12lead ECG , laboratory result serum chemistry , hematology , urinalysis perform within 21 day first dose . For renal function test , value must within normal laboratory reference range Women must postmenopausal least 2 year , surgically sterile , abstinent , practice agree practice effective method birth control sexually active entry throughout study ( effective method birth control include intrauterine device , doublebarrier method , male partner sterilization ) . Prescription hormonal contraceptive must use combination another method birth control ( e.g. , doublebarrier method ) throughout study . Women childbearing potential must negative serum pregnancy test result screening , negative urine test baseline ( Day 1 ) . Diagnosis schizoaffective disorder ( 295.70 ) accord DSMIV Meet DSMIV criterion rapid cycle DSMIV diagnosis alcohol substance dependence , exception nicotine caffeine dependence , within 12 month screen . Intermittent substance abuse month screen exclusionary , depend upon clinical judgment investigator , exception barbiturate Acute substance abuse , evidence positive urine drug screen screen baseline ( Day 1 ) Positive alcohol test screening baseline ( Day 1 ) Current suicidal ideation violent tendency time screen Involuntarilyhospitalized subject Moderate severe tardive dyskinesia time screen History neuroleptic malignant syndrome History bone marrow depression acute intermittent porphyria History positive result screen serology test ( hepatitis B , C , human immunodeficiency virus [ HIV ] ) History presence relevant cardiovascular ( include myocardial infarct cardiac arrhythmia ) , respiratory , neurologic ( include seizure ) , renal , hepatic , gastrointestinal ( include surgery , severe gastrointestinal narrowing , malabsorption problem ) , endocrine , hematologic , immunologic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Bipolar I disorder</keyword>
	<keyword>mood disorder</keyword>
	<keyword>antipsychotic drug</keyword>
	<keyword>enzyme inducer</keyword>
	<keyword>Paliperidone ER</keyword>
</DOC>